Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply - Aix-Marseille Université Accéder directement au contenu
Article Dans Une Revue LANCET DIABETES & ENDOCRINOLOGY Année : 2022

Dates et versions

hal-03780355 , version 1 (18-04-2023)

Identifiants

  • HAL Id : hal-03780355 , version 1

Citer

Maria Fleseriu, Frederic Castinetti, Monica Gadelha, Andrea Giustina, Andre Lacroix, et al.. Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Reply. LANCET DIABETES & ENDOCRINOLOGY, 2022, 10 (6), pp.385-387. ⟨hal-03780355⟩
29 Consultations
23 Téléchargements

Partager

Gmail Mastodon Facebook X LinkedIn More